These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36763251)

  • 41. 25-hydroxyvitamin D levels and juvenile idiopathic arthritis: is there an association with disease activity?
    Pelajo CF; Lopez-Benitez JM; Kent DM; Price LL; Miller LC; Dawson-Hughes B
    Rheumatol Int; 2012 Dec; 32(12):3923-9. PubMed ID: 22198692
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Using the Juvenile Arthritis Disease Activity Score based on erythrocyte sedimentation rate or C-reactive protein level: results from the Portuguese register.
    Mourão AF; Santos MJ; Melo-Gomes J; Martins FM; Costa JA; Ramos F; Brito I; Duarte C; Figueira R; Figueiredo G; Furtado C; Lopes A; Oliveira M; Rodrigues A; Salgado M; Sousa M; Branco JC; Fonseca JE; Canhão H
    Arthritis Care Res (Hoboken); 2014 Apr; 66(4):585-91. PubMed ID: 25354266
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An investigation into the relationship between nutritional status, dietary intake, symptoms and health-related quality of life in children and young people with juvenile idiopathic arthritis: a systematic review and meta-analysis.
    Zare N; Mansoubi M; Coe S; Najafi AA; Bailey K; Harrison K; Sheehan J; Dawes H; Barker K
    BMC Pediatr; 2023 Jan; 23(1):3. PubMed ID: 36593466
    [TBL] [Abstract][Full Text] [Related]  

  • 44. MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis.
    Anink J; Van Suijlekom-Smit LW; Otten MH; Prince FH; van Rossum MA; Dolman KM; Hoppenreijs EP; ten Cate R; Ursu S; Wedderburn LR; Horneff G; Frosch M; Vogl T; Gohar F; Foell D; Roth J; Holzinger D
    Arthritis Res Ther; 2015 Aug; 17(1):200. PubMed ID: 26249667
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cytokine Biomarkers of Disease Activity and Therapeutic Response after Initiating Methotrexate Therapy in Patients with Juvenile Idiopathic Arthritis.
    Funk RS; Chan MA; Becker ML
    Pharmacotherapy; 2017 Jun; 37(6):700-711. PubMed ID: 28475276
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bone mineral density in egyptian children with juvenile idiopathic arthritis: possible correlation to serum RANKL / osteoprotegerin (OPG) ratio and OPG gene polymorphisms.
    Eid R; Abdelsalam M; Fathy AA; Abolenein HM; Elmarghany EB; El-Hanafy AA; Hamdy N; Abd-Elmagid DS; Niazy NA; Abd-El Ghaffar DM
    Pediatr Rheumatol Online J; 2023 Jun; 21(1):58. PubMed ID: 37328895
    [TBL] [Abstract][Full Text] [Related]  

  • 47. PROMIS Computer Adaptive Tests and Their Correlation With Disease Activity in Juvenile Idiopathic Arthritis.
    Trachtman R; Wang CM; Murray E; Szymonifka J; Pan N; Adams AB; Taber SF; Onel KB; Mandl LA
    J Clin Rheumatol; 2021 Jun; 27(4):131-135. PubMed ID: 31743268
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Role of Interleukin 37 as a Novel Proangiogenic Factor in Juvenile Idiopathic Arthritis.
    El-Barbary AM; Hussein MS; Almedany SH; Rageh EM; Alsalawy AM; Aboelhawa MA; Elkholy RM; Shafik NM; Elharoun AS
    J Clin Rheumatol; 2019 Mar; 25(2):85-90. PubMed ID: 29683837
    [TBL] [Abstract][Full Text] [Related]  

  • 49. How common is clinically inactive disease in a prospective cohort of patients with juvenile idiopathic arthritis? The importance of definition.
    Shoop-Worrall SJW; Verstappen SMM; Baildam E; Chieng A; Davidson J; Foster H; Ioannou Y; McErlane F; Wedderburn LR; Thomson W; Hyrich KL
    Ann Rheum Dis; 2017 Aug; 76(8):1381-1388. PubMed ID: 28389553
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Serum calprotectin (S100A8/A9): a promising biomarker in diagnosis and follow-up in different subgroups of juvenile idiopathic arthritis.
    La C; Lê PQ; Ferster A; Goffin L; Spruyt D; Lauwerys B; Durez P; Boulanger C; Sokolova T; Rasschaert J; Badot V
    RMD Open; 2021 Jun; 7(2):. PubMed ID: 34108235
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Elevated serum resistin in juvenile idiopathic arthritis: relation to categories and disease activity.
    Gheita TA; El-Gazzar II; El Shazly RI; El-Din AM; Abdel-Rasheed E; Bassyouni RH
    J Clin Immunol; 2013 Jan; 33(1):297-301. PubMed ID: 22886618
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Arthritis in children: comparison of clinical and biological characteristics of septic arthritis and juvenile idiopathic arthritis.
    Aupiais C; Basmaci R; Ilharreborde B; Blachier A; Desmarest M; Job-Deslandre C; Faye A; Bonacorsi S; Alberti C; Lorrot M
    Arch Dis Child; 2017 Apr; 102(4):316-322. PubMed ID: 27655660
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Serum and salivary inflammatory biomarkers in juvenile idiopathic arthritis-an explorative cross-sectional study.
    Cetrelli L; Lundestad A; Gil EG; Fischer J; Halbig J; Frid P; Angenete O; Rosén A; Tylleskär KB; Luukko K; Nordal E; Åstrøm AN; Skeie MS; Stunes AK; Bletsa A; Sen A; Feuerherm AJ; Rygg M
    Pediatr Rheumatol Online J; 2024 Mar; 22(1):36. PubMed ID: 38461338
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Serum calreticulin as a novel biomarker of juvenile idiopathic arthritis disease activity.
    Hashaad NI; Fawzy RM; Elazem AA; Youssef MI
    Eur J Rheumatol; 2017 Mar; 4(1):19-23. PubMed ID: 28293448
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Elevated BAFF (BLyS) and APRIL in Juvenile idiopathic arthritis patients: relation to clinical manifestations and disease activity.
    Gheita TA; Bassyouni IH; Emad Y; el-Din AM; Abdel-Rasheed E; Hussein H
    Joint Bone Spine; 2012 May; 79(3):285-90. PubMed ID: 21733733
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inflammatory Markers and Disease Activity in Juvenile Idiopathic Arthritis.
    Sarkar S; Alam MM; Das G; Datta S
    Indian J Pediatr; 2017 May; 84(5):349-356. PubMed ID: 28176230
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.
    Schmeling H; Minden K; Foeldvari I; Ganser G; Hospach T; Horneff G
    Arthritis Rheumatol; 2014 Sep; 66(9):2580-9. PubMed ID: 24942886
    [TBL] [Abstract][Full Text] [Related]  

  • 58. S100A12 Is Associated with Response to Therapy in Juvenile Idiopathic Arthritis.
    Gohar F; Anink J; Moncrieffe H; Van Suijlekom-Smit LWA; Prince FHM; van Rossum MAJ; Dolman KM; Hoppenreijs EPAH; Ten Cate R; Ursu S; Wedderburn LR; Horneff G; Frosch M; Foell D; Holzinger D
    J Rheumatol; 2018 Apr; 45(4):547-554. PubMed ID: 29335345
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Procalcitonin Differs in Children With Infection and Children With Disease Flares in Juvenile Idiopathic Arthritis.
    Trachtman R; Murray E; Wang CM; Szymonifka J; Toussi SS; Walters H; Nellis ME; Onel KB; Mandl LA
    J Clin Rheumatol; 2021 Apr; 27(3):87-91. PubMed ID: 31693652
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tocilizumab treatment in juvenile idiopathic arthritis patients: A single center experience.
    Demir S; Sönmez HE; Arslanoğlu-Aydın E; Özen S; Bilginer Y
    Turk J Pediatr; 2019; 61(2):180-185. PubMed ID: 31951328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.